Browse regulations

These Regulations establish the procedural requirements for claiming repayment of the overseas transfer charge under s244A Finance Act 2004. They specify: how claims must be submitted (form, content, declarations); information required about members, transfers and circumstances; HMRC's obligations to request missing information or issue repayment references; appeal rights; and determines which parties receive repayments in various scenarios (member, scheme administrator, scheme manager) including handling of scheme mergers, cessations, and ring-fenced transfer funds.

The overseas transfer charge itself (s244A) represents a punitive 25% withholding tax on cross-border pension transfers, penalising mobile workers and discouraging international capital flows. These Regulations, rather than merely providing neutral administrative machinery, embed and legitimise this distortionary charge by creating an elaborate bureaucratic process that presupposes the charge's validity. The complex rules governing who receives repayments (members, scheme administrators, scheme managers), handling of mergers/cessations, and attribution to ring-fenced funds add compliance costs and uncertainty without addressing the fundamental problem: the charge itself impedes the free movement of capital and labour that Adam Smith's invisible hand requires. A truly free-trading Britain would not maintain such barriers to cross-border financial flows.

EU Exit amendment to Human Medicines Regulations 2012, establishing UK-specific definitions for advanced therapy medicinal products (gene therapy, somatic cell therapy, tissue engineered products), creating separate regulatory frameworks for Great Britain and Northern Ireland, modifying marketing authorisation definitions (UKMA(GB), UKMA(NI), UKMA(UK)), and setting out good manufacturing practice principles for post-Brexit pharmaceutical regulation.

While this regulation inherits and maintains significant EU-derived pharmaceutical bureaucracy, deletion would create a regulatory vacuum in critical areas: advanced therapy definitions (gene therapy, cell therapy, tissue engineering) provide essential safety frameworks for these novel treatments; the GB/NI split maintains necessary distinctions required by the Ireland/Northern Ireland Protocol; and removing the good manufacturing practice provisions would leave UK pharmaceutical quality standards undefined. The regulation enables UK to develop independent pharmaceutical policy and potentially streamline approvals, but删除ing it wholesale would harm public health and create legal uncertainty rather than reduce actual regulatory burden.

EU Exit statutory instrument that removes EU law references from UK healthcare regulations, amending the NHS Acts 2006, NHS Business Services Authority Order 2005, and various NHS Regulations 2013-2015 to delete references to EU social security coordination regulations (1408/71, 574/72, 883/2004, 987/2009) and European Health Insurance Cards, replacing them with references to new 'listed healthcare arrangements' under the Healthcare (EEA and Switzerland Arrangements) (EU Exit) Regulations 2019.

This regulation inherits and perpetuates the EU's bureaucratic reciprocal healthcare bureaucracy post-Brexit. Rather than seizing regulatory independence, it merely renames EHIC references to 'EHIC equivalent documents' and maintains an elaborate document-based coordination system that will impose compliance costs on NHS administrative staff and healthcare providers. The original EU framework created distortions by treating healthcare as a social security coordination matter rather than allowing bilateral market-based arrangements. Critically, by keeping the EU coordination apparatus in place for non-UK-issued documents while only removing UK-issued ones, it maintains discriminatory treatment based on document origin that will confuse patients and providers alike.

These Brexit regulations remove EU-derived healthcare provisions from UK law, including sections 6A/6B/6BA/6BB of the NHS Act 2006 (reimbursement for EEA state treatment and prior authorization requirements), revoke the 2013 Cross-Border Healthcare Regulations implementing EU Directive 2011/24/EU, and replace EU regulatory references with UK equivalents. The regulations also revoke two EU Commission Decisions on eHealth networks and contain transitional provisions maintaining limited reimbursement obligations for one year after IP completion day for services provided before Brexit.

These regulations remove valuable EU-derived patient rights (cross-border healthcare access in EEA states) that provided rare competitive pressure on the NHS monopoly, without offering any liberalizing replacement. The regulation merely swaps EU-imposed rules for UK versions of the same restrictions—maintaining prior authorization requirements and bureaucratic controls while eliminating patient choice. The NHS's near-monopoly position is preserved, not challenged. The transitional provisions show the regulation acknowledges ongoing obligations but only for a limited period, leaving patients worse off long-term. From a free-market perspective, this regulation benefits NHS institutional interests over patient welfare by removing external competitive discipline.

EU Exit statutory instrument that: (1) accredits established EU, Icelandic, and Norwegian natural mineral waters for continued sale in England after Brexit, with administrative machinery for accreditation cessation; (2) amends Regulation (EU) 1169/2011 on food information to replace EU Commission implementing powers with UK domestic regulation-making powers; (3) amends Regulation (EC) 1830/2003 on GMO traceability to add UK devolved authority definitions and replace EU Commission powers with UK regulatory powers.

This regulation perpetuates EU-derived bureaucratic mechanisms rather than dismantling them. The natural mineral water accreditation system creates government-maintained lists, publication requirements, and notification procedures that restrict free trade in bottled waters without justification—the market and private certification could handle water quality recognition. The regulation merely relocates EU regulatory control to UK authorities without reducing burden. While some EU Exit amendments are necessary to prevent legal gaps, this regulation goes beyond technical fixes by establishing new UK administrative apparatus (the 'paragraph 9 list', accreditation cessation dates, notification requirements to foreign authorities) that will persist beyond any reasonable transition period. These provisions should be deleted and replaced with simple market-based recognition of equivalent third-country standards.

EU Exit regulations amending criminal justice legislation to reflect Brexit, revoking EU-derived regulations (EPO Regulations, Protocol No. 36 Regulations, financial penalties recognition) while preserving transitional provisions for cases received before IP completion day. Also removes 'member State' references from PACE 1984 and Northern Ireland equivalents.

While this regulation ultimately should be deleted once the transition period ends and these EU-era mutual recognition mechanisms are fully replaced, deletion now would create legal chaos. These provisions provide essential transitional continuity for cases already in progress under EU frameworks (European Protection Orders, supervision measures, financial penalties received before IP completion day). Removing them immediately would leave courts with no legal basis to handle legitimate pending cases, harming both victims and defendants. The regulation represents proper parliamentary sovereignty over retained EU law—it actively revokes EU regulations and removes 'member State' references rather than passively retaining them. The transitional savings are narrowly tailored to pre-existing cases, not indefinite EU supremacy.

Amendment to Judicial Pensions Regulations 2015 and Judicial Pensions (Fee-Paid Judges) Regulations 2017, extending the contribution rate tables for the scheme year 1st April 2019 to 31st March 2020. These are technical amendments updating dates in existing pension contribution frameworks.

These are routine administrative amendments extending pension contribution rate tables by one year. Without these updates, there would be a legal gap in the pension contribution framework for fee-paid judges during the 2019-2020 period, potentially creating uncertainty around contribution calculations. Deletion would leave the underlying 2015 and 2017 regulations intact but without the necessary annual updates, causing administrative confusion rather than regulatory burden relief.

Post-Brexit statutory instrument that amends multiple UK regulations (Rabies Importation Order 1974, Artificial Insemination of Pigs Regulations 1992, Animals Post-Import Control Order 1995, Bovine Embryo Regulations 1995, Pet Animals Order 2011, and Bovine Semen Regulations 2007) to replace EU-related terminology with UK-specific references. Replaces references to 'another Member State' with 'a', 'intra-Community trade' with 'trade within Great Britain' or 'national trade', and EU directives with corresponding UK regulations. Essentially updates cross-references to function in a post-EU legal environment.

While this regulation merely renames EU-centric terminology rather than reducing substantive regulatory burden, deletion would create legal chaos. Without these amendments, the referenced regulations would contain nonsensical references to EU directives and Member State obligations that no longer apply to the UK. The amendments are necessary technical corrections to maintain functional legislation post-Brexit, not new regulatory burdens. However, this illustrates how Brexit regulatory independence remains incomplete—Parliament should pursue genuine deregulation in these areas rather than simply substituting 'UK' for 'EU' in regulatory text.

EU Exit Regulations 2019 amending EU Commission Implementing Regulations (215/2014, 240/2014, 480/2014, 821/2014, 964/2014, 2015/1076, 2015/1516) to make them operable in UK law post-Brexit. Replaces EU-centric references (Member States, Commission, ESI Funds, Union) with UK references (relevant authority, constituent nation) for support for rural development and support under Regulation 508/2014 (fisheries). Also revokes Regulations 184/2014, 1011/2014 and Commission Decision 2014/660 to the extent they apply to EAFRD and EMFF.

This is a Brexit technical amendment that merely adapts existing EU regulations for post-exit UK use. Without it, a legal vacuum would exist for rural development and fisheries funding frameworks. The regulation does not create new regulatory burdens but mechanically updates references. The underlying policy decisions about rural development and fisheries support are separate from this amendment, which simply ensures legal continuity. Deleting it would harm UK beneficiaries of these support schemes without eliminating any substantive regulatory requirement.

EU Exit regulation that removes EU-derived cross-border healthcare frameworks from Northern Ireland law, including the Health Services (Cross-Border Health Care) Regulations 2013 and Articles 14B-14E of the 1972 Order (EEA healthcare reimbursement). Maintains transitional savings for qualifying EEA expenditure incurred before IP completion day and preserves limited prescribing rights for EEA nationals receiving treatment before Brexit.

This regulation primarily removes regulatory burden by eliminating EU-derived cross-border healthcare frameworks that no longer apply post-Brexit. However, the transitional savings provisions are necessary to prevent unfairness to individuals who made legitimate healthcare decisions and incurred expenses under the previous legal framework. Without these savings, UK nationals and EEA nationals who relied on these provisions before IP completion day would face unjust financial liability for costs they had no reason to anticipate would fall on them. The regulation achieves the goal of removing the EU framework while providing targeted, time-limited protections for those who made decisions based on the previous law — a reasonable transitional measure rather than permanent regulatory entrenchment.

Post-Brexit statutory instrument amending EU Regulation 1303/2013 (Common Provisions for ESI Funds) to replace EU institutional references with UK authorities for rural development support. Replaces 'Member State' with 'relevant authority', removes EU Commission oversight, and adapts definitions for UK implementation. The programmes covered ran from 2014-2020.

This is a technical amendment adapting retained EU law for post-Brexit use. Deleting it would create a legal vacuum without removing the underlying retained EU regulations (the European Union (Withdrawal) Act 2018 preserves the substantive rules). The amendment merely shifts institutional responsibility from EU bodies to UK authorities (Secretary of State, Scottish Ministers, Welsh Ministers, DAERA) without substantively expanding regulatory burden. While the underlying CAP-style rural development framework has criticisms, this amendment does not itself impose new regulatory costs—it merely corrects references to make existing law functional. Removing it would cause administrative chaos without actually eliminating the retained EU regulatory framework.

Amends the 2012 NHS Commissioning Regulations by updating two specific payment thresholds: the flat rate payment increases from £158.16 to £165.56, and the high band payment increases from £217.59 to £227.77. These appear to be commissioned service payment rates under the NHS system.

This amendment perpetuates government-mandated price controls within the NHS centralised commissioning system. While merely adjusting for inflation, it keeps in place a fixed-pricing mechanism that suppresses market signals and contributes to the systemic inefficiencies of the NHS near-monopoly. The unseen costs include perpetuating a system that discourages private healthcare alternatives and distorts resource allocation away from what competitive markets would produce.

This Order removes North Devon District Council's status as a competent harbour authority under the Pilotage Act 1987, effective 30 April 2019. It also makes a technical amendment to the Ilfracombe Harbour Revision Order 1996, correcting a cross-reference to an earlier harbour order.

This instrument is deregulatory in nature — it removes a regulatory function (pilotage authority status) rather than imposing one. Removing unnecessary harbour authority designations simplifies the administrative structure of maritime governance without creating a regulatory gap, as responsibility would transfer to the relevant harbour authority. The technical amendment correcting a cross-reference also removes potential confusion. No harm to Britons results from deleting this streamlined, deregulatory Order.

The Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 amend the Medical Devices Regulations 2002 to implement post-Brexit regulatory changes. Key changes include: replacing EU references with UK equivalents (Great Britain instead of Community), creating a 'designated standard' framework allowing the Secretary of State to designate technical specifications from CEN, CENELEC, or BSI, introducing 'UK responsible person' requirements for non-UK manufacturers, permitting qualifying Northern Ireland goods to access the Great Britain market, and revoking retained EU regulations (MDR, IVDR) on specified future dates with transitional provisions. The regulation applies to England, Wales, and Scotland.

This SI is a prime example of inherited EU law without democratic scrutiny — it transferred the EU's entire medical devices regulatory apparatus into UK law with minimal substantive change, merely replacing 'Community' with 'Great Britain.' It retains the precautionary, compliance-heavy approach without leveraging post-Brexit independence to create a more competitive, proportionate framework. The 'designated standard' system still relies heavily on EU standards bodies (CEN, CENELEC). The new UK responsible person requirement adds costs for non-UK manufacturers without clear benefit. This regulation represents a squandered opportunity to establish genuinely independent, market-oriented medical device regulation that could have attracted global investment and reduced healthcare costs for Britons.

The Syria (Sanctions) (EU Exit) Regulations 2019 implement a sanctions regime against Syria following Brexit, retained from EU law. The regulations establish: designation criteria for individuals and entities involved with the Assad regime; asset-freeze prohibitions on designated persons; trade restrictions on arms, chemical weapons-related items, internal repression goods, and surveillance technology; prohibitions on Assad regime bonds; director disqualification sanctions; and immigration exclusions for designated persons. The stated purposes include promoting peace, stability, human rights, and democracy in Syria, and providing accountability for gross human rights violations by the Assad regime. The regulations define 'the Assad regime' specifically as the regime led by Bashar Al-Assad from 9th May 2011 to 8th December 2024.

The definition of 'the Assad regime' is explicitly bounded by an end date of 8th December 2024, indicating these sanctions were calibrated to a specific regime that has now ceased to exist. The regulation's own interpretive framework acknowledges the temporal limitation of the sanctions' purpose. Keeping these provisions in force would impose ongoing compliance costs, restrict legitimate trade and financial services, and create regulatory uncertainty for businesses seeking to engage with a post-conflict Syria. The intended beneficiaries of these sanctions—the Syrian people—would be better served by removing barriers to humanitarian assistance, reconstruction trade, and economic engagement with a transitioning society.